FDA reviewers found no serious safety or efficacy concerns with Moderna’s mRNA influenza vaccine for adults 50 and over ahead of a key advisory panel meeting. This marks a significant moment in the health & science landscape, with potential ripple effects for various groups.
The study adds to a growing body of research on this topic, contributing to our understanding of key issues.
For those seeking more in-depth information, the linked source offers additional context and reporting on this topic.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources: